HORIZON THERAPEUTICS PLC (HZNP) Forecast, Price Target & Analyst Ratings
NASDAQ:HZNP • IE00BQPVQZ61
116.3 USD
+0.05 (+0.04%)
At close: Oct 5, 2023
116.34 USD
+0.04 (+0.03%)
After Hours: 10/5/2023, 8:25:26 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HORIZON THERAPEUTICS PLC (HZNP).
Forecast Snapshot
Consensus Price Target
$118.83
+ 2.18% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ3 / 2023
EPS Estimate$1.24
Revenue Estimate987.18M
ChartMill Buy Consensus
50.91%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$118.83
Upside
+ 2.18%
From current price of $116.30 to mean target of $118.83, Based on 11 analyst forecasts
Low
$117.67
Median
$118.83
High
$122.33
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
11 analysts have analysed HZNP and the average price target is 118.83 USD. This implies a price increase of 2.18% is expected in the next year compared to the current price of 116.3.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
50.91%
HZNP was analyzed by 11 analysts. The buy percentage consensus is at 51. So analysts seem to be rather neutral about HZNP.
In the last month the buy percentage fell by 24 points. So the trust of analysts is decreasing.
HZNP was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-12-13 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-12-13 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2022-12-13 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-12-13 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2022-12-12 | Stifel | Downgrade | Buy -> Hold |
| 2022-12-07 | Piper Sandler | Maintains | Overweight |
| 2022-11-03 | SVB Leerink | Maintains | Outperform |
| 2022-11-01 | HC Wainwright & Co. | Initiate | Neutral |
| 2022-10-25 | Piper Sandler | Maintains | Overweight |
| 2022-08-04 | BMO Capital | Maintains | Outperform |
| 2022-08-04 | UBS | Downgrade | Buy -> Neutral |
| 2022-08-04 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2022-08-04 | Goldman Sachs | Maintains | Buy |
| 2022-08-04 | Morgan Stanley | Maintains | Overweight |
| 2022-07-05 | UBS | Maintains | Buy |
| 2022-06-14 | UBS | Initiate | Buy |
| 2022-05-24 | SVB Leerink | Initiate | Market Perform |
| 2022-05-23 | SVB Leerink | Initiate | Market Perform |
| 2022-05-05 | Morgan Stanley | Maintains | Overweight |
| 2022-03-02 | Morgan Stanley | Maintains | Overweight |
| 2021-12-08 | Wells Fargo | Initiate | Overweight |
| 2021-11-19 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2021-08-26 | Morgan Stanley | Maintains | Overweight |
| 2021-08-24 | Goldman Sachs | Maintains | Neutral |
| 2021-08-05 | BMO Capital | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ3 / 2023
EPS Estimate$1.24
Revenue Estimate987.18M
Revenue Q2Q6.68%
EPS Q2Q-0.72%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-4.34%
EPS (1 Month)
0.00%
EPS (3 Months)
-14.76%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 4.34% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.2B 69.26% | 3.226B 46.63% | 3.629B 12.48% | 3.881B 6.94% | 4.411B 13.66% | 4.939B 11.97% | 5.453B 10.41% | 5.905B 8.29% | 6.279B 6.33% | 6.708B 6.83% | 6.704B -0.06% | |
| EBITDA YoY % growth | 764.7M 104.03% | 907.249M 18.64% | 1.12B 23.48% | 1.442B 28.72% | 1.886B 30.79% | 2.048B 8.59% | 2.622B 28.03% | 3.02B 15.18% | 3.353B 11.03% | 3.657B 9.07% | 3.658B 0.03% | |
| EBIT YoY % growth | 485.2M 252.62% | 553.498M 14.08% | 729.833M 31.86% | 1.307B 79.08% | 1.852B 41.70% | 2.279B 23.06% | 2.83B 24.18% | 3.261B 15.23% | 3.7B 13.46% | 4.149B 12.14% | 4.149B | |
| Operating Margin | 22.05% | 17.16% | 20.11% | 33.68% | 41.99% | 46.14% | 51.90% | 55.22% | 58.93% | 61.85% | 61.89% | |
| EPS YoY % growth | 3.82 91.96% | 4.81 25.92% | 4.87 1.25% | 4.63 -5.01% | 5.77 24.83% | 6.82 18.16% | 9.08 33.08% | 10.20 12.27% | 11.26 10.46% | 12.39 9.98% | 12.53 1.14% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.24 -0.72% | 1.42 17.74% | 1.07 29.04% | 1.38 14.75% | 1.58 27.40% | 1.60 12.41% |
| Revenue Q2Q % growth | 987.18M 6.68% | 1.082B 14.86% | 1.004B 20.66% | 1.014B 7.31% | 1.099B 11.33% | 1.142B 5.55% |
| EBITDA Q2Q % growth | 399.87M -15.14% | 512.9M -14.74% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 337.67M 88.01% | 371.65M 75.99% | 409.53M 1,037.77% | 497.05M 252.92% | 537.74M 59.25% | 594.35M 59.92% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
11.90%
EPS Next 5 Year
15.92%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
10.34%
Revenue Next 5 Year
9.94%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
14.62%
EBIT Next 5 Year
17.30%
HORIZON THERAPEUTICS PLC / HZNP Forecast FAQ
What is the price target for HZNP stock?
11 analysts have analysed HZNP and the average price target is 118.83 USD. This implies a price increase of 2.18% is expected in the next year compared to the current price of 116.3.
What are the consensus estimates for HZNP stock next earnings?
The consensus EPS estimate for the next earnings of HORIZON THERAPEUTICS PLC (HZNP) is 1.24 USD and the consensus revenue estimate is 987.18M USD.
How many analysts cover HORIZON THERAPEUTICS PLC (HZNP) stock?
The number of analysts covering HORIZON THERAPEUTICS PLC (HZNP) is 11.